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Timely and selective recruitment of transcription
factors to their appropriate DNA-binding sites repre-
sents a critical step in regulating gene activation;
however, the regulatory strategies underlying each
factor’s effective recruitment to specific promoter
and/or enhancer regions are not fully understood.
Here, we identify an unexpected regulatory mecha-
nism by which promoter-specific binding, and there-
fore function, of peroxisome proliferator-activator
receptor g (PPARg) in adipocytes requires G protein
suppressor 2 (GPS2) to prime the local chromatin
environment via inhibition of the ubiquitin ligase
RNF8 and stabilization of the H3K9 histone demethy-
lase KDM4A/JMJD2. Integration of genome-wide
profiling data indicates that the pioneering activity
of GPS2/KDM4A is required for PPARg-mediated
regulation of a specific transcriptional program,
including the lipolytic enzymes adipose triglyceride
lipase (ATGL) and hormone-sensitive lipase (HSL).
Hence, our findings reveal that GPS2 exerts a bio-
logically important function in adipose tissue lipid
mobilization by directly regulating ubiquitin signaling
and indirectly modulating chromatin remodeling to
prime selected genes for activation.INTRODUCTION
Members of the nuclear receptor superfamily of transcription
factors play critical roles in a variety of developmental processes
and in maintaining homeostasis of different organs. Nuclear
receptor transcriptional activity is mediated by the recruit-
ment of specific cofactors that are responsible for promoting
chromatin-remodeling events conducive to gene activation
or repression, with the exchange between corepressors and
coactivators being a highly regulated process often induced by
ligand binding (Glass and Rosenfeld, 2000; Perissi and Rose-nfeld, 2005; Hager et al., 2009). Among the nuclear receptors,
the peroxisome proliferator-activator receptors (PPARs) and
liver X receptors (LXRs) are critical for the development and
the functional regulation of key metabolic organs, the adipose
tissue and the liver, respectively, with both receptors forming
functional heterodimers with the retinoid X receptor (RXR).
PPARg, in particular, is known as the master regulator of adipo-
cyte differentiation and a critical factor for the regulation of lipid
metabolism, immunity, and insulin sensitivity (Rosen and Spie-
gelman, 2001; Hong and Tontonoz, 2008; Sonoda et al., 2008).
Genome-wide studies of transcription factor binding, histone
modifications, and chromatin-remodeling events have revealed
that an epigenomic transition state is initiated within hours of
stimulating adipogenesis. This dramatic reorganization of the
preadipocyte chromatin landscape includes early transcription
factors (CCAAT-enhancer-binding protein b [C/EBPb], gluco-
corticoid receptor [GR], RXR, and signal transducer and acti-
vator of transcription 5 [STAT5]) binding to DNA, transient chro-
matin opening, and changes in histone marks (Lefterova et al.,
2008; Nielsen et al., 2008; Mikkelsen et al., 2010; Steger
et al., 2010; Siersbæk et al., 2011). Interestingly, the so-called
‘‘adipogenic hot spots’’ where these changes occur during the
very first few hours of differentiation are often found occupied
by PPARg in mature adipocytes, suggesting that early remodel-
ing events could affect PPARg binding at later stages (Steger
et al., 2010).
Among others, lysine methylation is a prominent posttransla-
tional modification of histones that regulates chromatin struc-
ture, with Histone 3 Lysine 9 (H3K9) and Lysine 27 (H3K27)
trimethyl marks being recognized as hallmarks of gene repres-
sion. H3K9me3 in particular correlates with constitutive hetero-
chromatin, whereas demethylation of H3K9 is associated with
gene activation (Hublitz et al., 2009). KDM4/JMJD2 is a family
of Jmjc domain-containing demethylases responsible for H3K9
and H3K36 demethylation. Overexpression of the KDM4 pro-
teins associates with changes in chromatin remodeling that
modulate gene expression and promote cell proliferation, inva-
sion, and other oncogenic properties (Berry and Janknecht,
2013; Black et al., 2013; Young and Hendzel, 2013). Members
of this family have been associated with transcriptional activa-
tion mediated by nuclear receptors, such as estrogen andCell Reports 8, 163–176, July 10, 2014 ª2014 The Authors 163
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Figure 1. GPS2 Genome-wide Localization during 3T3-L1 Adipogenesis
(A) Venn diagram of the distribution of GPS2 ChIP-seq peaks before (day 0) and after (day 6) differentiation. Peaks are divided among promoters (1 kb/+400 bp
from RefSeq TSS), enhancers (distal sites positive for H3K4me1 mark), and other locations (distal sites negative for H3K4me1 mark) (Mikkelsen et al., 2010).
(B) Box plot showing GPS2-binding intensity on promoters, enhancers, other locations.
(legend continued on next page)
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androgen receptors (ERs and ARs, respectively), or by other
transcription factors that play critical roles during adipocyte dif-
ferentiation (Zhang et al., 2005; Guo et al., 2012; Berry and Jan-
knecht, 2013).
G protein suppressor 2 (GPS2) is a small protein, originally
identified while screening for suppressors of Ras activation in
the yeast pheromone response pathway, that exerts critical
anti-inflammatory roles in adipocytes and macrophages and is
significantly downregulated in human obesity (Spain et al.,
1996; Zhang et al., 2002; Cardamone et al., 2012; Toubal et al.,
2013). Although GPS2 is known to interact with various tran-
scriptional regulators, including histone acetyltransferases,
DNA repair proteins, and DNA-binding transcription factors
(Peng et al., 2000, 2001; Lee et al., 2006; Sanyal et al., 2007;
Zhang et al., 2008; Jakobsson et al., 2009), a clear understand-
ing of the molecular mechanism of GPS2 transcriptional function
remains strikingly incomplete. Moreover, whereas GPS2 is
thought to act as a coactivator for some transcription factors,
its identification as an intrinsic component of the nuclear recep-
tor corepressor (NCoR)/silencing mediator for retinoid and
thyroid hormone receptors (SMRT) complex is suggestive of a
repressive role (Zhang et al., 2002). Accordingly, recent studies
indicate that GPS2, together with the associated corepressor
SMRT, is downregulated in the adipose tissue of obese individ-
uals, where it plays a critical role in the regulation of a proinflam-
matory gene program (Toubal et al., 2013).
In addition to its transcriptional activity, GPS2 plays an impor-
tant role in maintaining basal regulation of c-Jun N-terminal
kinase (JNK) activity by inhibiting the enzymatic activity of
the tumor necrosis factor (TNF)-receptor associated factor 2
(TRAF2)/Ubc13 ubiquitin complex and preventing hyperactiva-
tion of the TNF-a signaling pathway (Zhang et al., 2002; Carda-
mone et al., 2012). In vivo relevance of this anti-inflammatory
role was confirmed in aP2-GPS2 transgenic mice by a protective
effect against diet-induced insulin resistance in adipose tissue
and by inhibition of TNF-a target gene activation in macro-
phages. However, aP2-driven overexpression of GPS2 is not
sufficient to ameliorate systemic insulin resistance in obese
mice and promotes hepatic steatosis (Cardamone et al., 2012).
Accordingly, GPS2 transgenic mice present elevated levels of
resistin (RETN), an adipokine first identified as a mediator of
insulin resistance in a murine obesity model (Steppan et al.,
2001; Cardamone et al., 2012). Because the regulation of
RETN expression in the adipose tissue is driven by a combina-
tion of PPARg and C/EBPa response elements (Tomaru et al.,
2009), we proposed that GPS2 might be acting as a coactivator
for PPARg (Cardamone et al., 2012).
Here, we have taken advantage of the functional connection
between GPS2 and PPARg to gain insights into strategies of se-
lective transcription factor recruitment to regulatory elements in
controlling gene transcription programs. Genome-wide localiza-
tion of GPS2 binding to chromatin in differentiating adipocytes
was instrumental to identify an unexpected regulatory strategy(C and D) Unclustered heatmaps displaying the localization of NCoR and SMRT
2008) around GPS2 peaks on GPS2-bound promoters and enhancers.
(E) Box plot of GPS2-binding intensity on PPARg-bound promoters, enhancers,
(F) Unclustered heatmaps showing the localization of GPS2-binding sites withinbased on GPS2 acting as a priming factor for PPARg recruitment
to a selected cohort of target genes, including the lipolysis
rate-limiting enzymes adipose triglyceride lipase (ATGL) and
hormone-sensitive lipase (HSL). Our findings indicate that regu-
lation of PPARg recruitment by GPS2 is specific to promoter
regions and depends on the inhibition of RNF8/Ubc13 enzymatic
activity and consequent stabilization of the histone demethylase
KDM4A/JMJD2.
RESULTS
GPS2 Transcriptional Role in Adipocytes
as a Coactivator for PPARg
Our previous work indicates that GPS2 regulates RETN gene
expression bymodulating PPARg transcriptional activity (Carda-
mone et al., 2012). Based on these results, we hypothesized that
GPS2 may play a widespread regulatory role in the adipose tis-
sue as a PPARg coactivator. To investigate the transcriptional
role of GPS2 and determine its genome-wide localization during
adipogenesis, we performed chromatin immunoprecipitation
followed by deep sequencing (ChIP-seq) in undifferentiated
(day 0) and differentiated (day 6) 3T3-L1 cells. A dramatic
increase in GPS2 binding to DNA upon differentiation was
observed, with 7,652 GPS2 peaks detected in undifferentiated
cells compared with 19,793 peaks in differentiated cells (Figures
1A and S1A). This 2- to 3-fold increase in GPS2 binding to
chromatin is consistently observed in each class when peaks
are divided among promoters, enhancers, and other locations
in the genome based on position in respect to RefSeq gene
definition and published H3K4me1 epigenetic signature in the
3T3-L1 cellular model (Mikkelsen et al., 2010) (Figures 1A and
S1A). However, GPS2 binding at promoter regions is found to
be stronger than at enhancers or other genomic locations, as
shown by increased median peak intensity (Figure 1B). Also,
although we detected a significant number of binding events
at gene promoters (33%–43%) and enhancer regions
(17%–20%), most GPS2 peaks were detected at nonpromoter/
nonenhancer regions (40%–47%), which leaves open the
interesting question of the role of GPS2 in these regions of
unknown functions that probably include other tissue-specific
regulatory elements (Figure S1A). Importantly, genes located
nearby GPS2 peaks were associated with a significant enrich-
ment in adipose-specific functions as indicated by Genomic Re-
gions Enrichment of Annotations Tool (GREAT) analysis (Fig-
ure S1B), thus further supporting a putative role for GPS2 in
adipogenesis.
Because GPS2 had been previously identified both as a
component of the NCoR/SMRT complex and as a coactivator
for a number of transcription factors, including the nuclear
receptors PPARg, LXR, and FXR (Zhang et al., 2002, 2008;
Jakobsson et al., 2009; Cardamone et al., 2012), we reasoned
that GPS2 could be responsible for both repressive and acti-
vating events during adipogenesis. Accordingly, GPS2 bindingpeaks (C) (Raghav et al., 2012) or PPARg and RXR peaks (D) (Lefterova et al.,
other locations at day 0 and day 6 of differentiation.
±1 kb of PPARg peaks on promoter and enhancer regions.
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is significantly enriched in proximity of genes that are both up-
and downregulated during adipogenesis, as defined based on
Pol2 occupancy or H3K36me3 pattern (Mikkelsen et al., 2010)
(Figures S1C and S1D). To address whether this dual transcrip-
tional role corresponds to GPS2 association with different bind-
ing partners, we overlapped the genome-wide localization
profile of GPS2 with comparable ChIP-seq data sets for NCoR,
SMRT, PPARg, and RXR as available in 3T3-L1 cells (Nielsen
et al., 2008; Lefterova et al., 2010; Raghav et al., 2012). As
predicted, a strong colocalization was observed with both core-
pressors and nuclear receptors, with GPS2 peaks overlapping
with NCoR/SMRT localization predominantly in undifferentiated
cells (GPS2-NCoR common peaks decrease from 1,196 to 804
on promoters and 333 to 224 on enhancers; GPS2-SMRT com-
mon peaks decrease from 1,125 to 531 on promoters and 366
to 115 on enhancers) (Figures 1C and S1E). The colocalization
of GPS2 and PPARg/RXR binding to regulatory regions instead
greatly increases upon differentiation (GPS2-RXR common
peaks increase from 612 to 3,591 on promoters and from 253
to 1,272 on enhancers; GPS2-PPARg common peaks increase
from 73 to 1,385 on promoters and 77 to 877 on enhancers) (Fig-
ures 1D and S1F). In both instances, the overlapping is more
significant on promoters than on enhancers and, as expected,
is absent on other genomic locations. Thus, these results
together confirm that GPS2 can be recruited to genes regulated
by nuclear receptors both as part of the corepressor complex
or independently of NCoR/SMRT.
Although our initial hypothesis of GPS2 acting as a coactivator
for PPARg was supported by the increase in overlapping be-
tween GPS2 and RXR/PPARg binding to promoter regions in
differentiated adipocytes, the relatively low number of common
peaks, as compared to the extensive gene program regulated
by PPARg, suggested a specificity for a dedicated subset
of target genes. To investigate this hypothesis and uncover
the molecular signature defining the common target genes,
we reanalyzed PPARg-binding profile by distinguishing peaks
located at promoters, enhancers, or other locations based on
the same definition of positioning and epigenetic marks used
for the GPS2 ChIP-seq data set. Remarkably, this analysis
revealed that colocalization of GPS2 and PPARg binding is sig-
nificantly concentrated on promoter regions, with almost 60%
(1,141 out of 2,012) of PPARg-bound promoters presenting
overlapping GPS2 peaks, whereas no significant overlapping is
observed over enhancers and other locations (Figures 1E and
1F). Hence, integrative analyses of GPS2 genome-wide localiza-
tion confirmed a dual role for GPS2 in the regulation of nuclear
receptor-mediated gene expression and indicated the existence
of a specific transcriptional program coregulated by GPS2 and
PPARg that is characterized by PPARg binding to promoter
regions, rather than to distal sites.
GPS2 Is Required for the Transcriptional Regulation
of Lipolytic Genes in Adipocytes
Intriguingly, gene ontology (GO) analysis of the identified tran-
scriptional program indicated a significant enrichment for
GPS2 and PPARg colocalization to genes that are important in
the regulation of lipolysis, hepatic steatosis, fatty acid oxidation,
and circulating levels of free fatty acids (FFA), whereas PPARg-166 Cell Reports 8, 163–176, July 10, 2014 ª2014 The Authorsdependent regulation of genes involved in brown fat differentia-
tion, regulation of glucose metabolism, and response to insulin
appears to be GPS2 independent (Table S1).
Among the genes that are cobound by GPS2 and PPARg, we
selected for further investigation two known targets of PPARg
transcriptional regulation, namely HSL and ATGL, due to their
critical roles as master regulators of lipolysis (Deng et al., 2006;
Kim et al., 2006; Kershaw et al., 2007; Lass et al., 2011). To
confirm that GPS2 regulates the expression of these genes
in vivo, we took advantage of the aP2-GPS2 transgenic mice
(Cardamone et al., 2012). Both RNA expression and protein
expression of HSL and ATGL were found upregulated in the
adipose tissue of GPS2 transgenic mice when compared to
wild-type (WT) littermates, similarly to the increase previously
reported for RETN (Figures 2A and 2B). Conversely, down-
regulation of GPS2 by small interfering RNA (siRNA) significantly
impairs their expression in differentiated 3T3-L1 cells (Figure 2C).
As expected, the expression of proinflammatory cytokines,
such as interleukin-6 (IL-6), is significantly upregulated, whereas
the expression of other known targets of PPARg regulation
is not affected by changes in GPS2 expression, further suggest-
ing the specificity of GPS2-PPARg functional interaction on a
selected subset of regulatory regions (Figure 2D).
Based on the observation that ectopic upregulation of ATGL
in mice is sufficient to drive elevated basal lipolysis (Ahmadian
et al., 2009), we reasoned that lipolysis in the adipose tissue of
aP2-GPS2 transgenic mice might be increased due to GPS2-
mediated upregulation of rate-limiting lipolytic enzymes. Indeed,
basal activation of HSL by phosphorylation is observed in the
adipose tissue of aP2-GPS2 mice (Figure 2E), confirming acti-
vation of the lipolytic pathway. Similarly, induced activation of
the lipolytic pathway by b-adrenergic stimulation is increased
in primary adipocytes isolated from epididymal fat of aP2-
GPS2 transgenic mice, as measured by phosphorylation of
HSL (Figure 2F).
In addition to being induced during adipogenesis, HSL and
ATGL gene expression is known to be upregulated upon lipolysis
induction (Festuccia et al., 2006; Chakrabarti et al., 2011); thus,
we asked whether GPS2 participates in their transcriptional
activation in response to the b-adrenergic receptor agonist
isoproterenol in 3T3-L1 cells. Also in this setting, GPS2 down-
regulation by siRNA significantly impaired the induced upregu-
lation of both HSL and ATGL (Figure 2G). To our surprise, ChIP
experiments in isoproterenol-stimulated 3T3-L1 cells indicated
that recruitment of PPARg to the HSL and ATGL promoters is
severely impaired upon siGPS2 transfection (Figure 2H). Thus,
our results confirm that GPS2 is a critical component of the
transcriptional machinery regulating basal and induced lipolysis
in the adipose tissue via modulation of the expression of two
rate-limiting enzymes, and suggest that loss of ATGL and HSL
gene activation in absence of GPS2 is due to impaired recruit-
ment of PPARg.
GPS2 Is Required for Chromatin Remodeling
of PPARg Target Genes
To further dissect the molecular mechanism of GPS2 transcrip-
tional actions on PPARg-regulated promoters, we first confirmed
that PPARg occupancy on RETN, HSL, and ATGL promoters
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Figure 2. GPS2 Is Required for Transcrip-
tional Regulation of Lipolytic Genes
(A) RT-qPCR analysis of ATGL, HSL, and RETN
gene expression in the white adipose tissue (WAT)
from WT and aP2-GPS2 transgenic mice.
(B) Western blot showing increase of ATGL and
HSL protein expression in the WAT of transgenic
mice.
(C and D) RT-qPCR analysis showing decreased
expression of ATGL, HSL, and RETN in 3T3-L1
cells transfected with siRNA against GPS2. No
significant changes are observed for PPARg, aP2,
and AdPLA, whereas IL-6 expression is upregu-
lated in absence of GPS2.
(E) Phosphorylation of Ser660 on HSL is increased
in aP2-GPS2 mice.
(F) Increased basal and induced phosphorylation of
HSL in WAT of aP2-GPS2 mice. ISO, isoproterenol.
(G) Impaired transcriptional activation of ATGL
and HSL upon ISO treatment in absence of GPS2
as shown by RT-qPCR analysis in 3T3-L1.
(H) ChIP for PPARg and GPS2 on the ATGL and
HSL promoters. IgG, immunoglobulin G.
All graphic data are ±SD, with corresponding
p values indicated as follow: *p < 0.08; **p < 0.05;
***p < 0.01.was indeed greatly diminished upon GPS2 downregulation
(Figure 3A). These results together suggest that GPS2 is not
being recruited to DNA by PPARg as a ‘‘classic’’ coactivator
but, rather, plays a function in priming regulatory regions for
the nuclear receptor binding. Indeed, comparison between
GPS2 and PPARg profiling indicated that GPS2 was already
bound at day 0 to most promoter regions that were later marked
by PPARg at day 6 (Figure 1F). Thus, we asked whether GPS2
could be required for dictating local changes in histone modifi-
cations necessary to regulate the permissiveness of the pro-
moter for transcription factor binding. Because demethylationCell Reports 8, 163–of H3K9 is a critical step toward gene acti-
vation, we first tested whether the pro-
moter methylation status was dependent
on GPS2. In concert with our hypothesis,
a significant increase in the repressive
mark trimethyl H3K9 (H3K9me3) was
observed on target promoters upon
GPS2 downregulation by siRNA (Fig-
ure 3B). We next investigated the recruit-
ment of the machinery responsible for his-
tone demethylation. Specific recruitment
of KDM4A (JMJD2A/JHDM3A), an H3K9
demethylase previously shown to interact
with NCoR/SMRT complex (Zhang et al.,
2005), was observed on the RETN pro-
moter and found to be dependent on
GPS2 (Figure 3C). Furthermore, in differ-
entiating 3T3-L1 cells, siRNA-mediated
knockdown of KDM4A significantly
impaired the recruitment of PPARg (Fig-
ure 3D) without affecting GPS2 (Fig-ure S2A). As a result, expression of the ATGL, HSL, and RETN
genes is significantly downregulated upon siKDM4A transfec-
tion (Figure 3E), thus confirming that KDM4A is required for
PPARg-dependent gene activation. Together, these results
support the hypothesis that GPS2 indirectly regulates PPARg
activity on three key metabolic genes by modulating its recruit-
ment via the pioneering activity of KDM4A-dependent H3K9
demethylation. Because this strategy would imply that both
GPS2 and KDM4A are already present on the ATGL, HSL, and
RETN promoters prior to PPARg recruitment, we performed a
kinetic analysis of the occupancy of these target promoters176, July 10, 2014 ª2014 The Authors 167
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Figure 3. GPS2 Is Required for PPARg Binding and Chromatin Remodeling of Target Genes
(A) ChIP for PPARg on ATGL and HSL promoters and for GPS2 and PPARg on RETN promoter.
(B) Increased H3K9Me3 in absence of GPS2 as measured by ChIP on HSL and RETN promoters.
(C) ChIP assay analysis of KDM4A recruitment on RETN promoter.
(D) ChIP assay analysis of PPARg recruitment on RETN and ATGL promoter.
(E) RT-qPCR analysis of KDM4A, RETN, HSL, and ATGL expression in differentiated 3T3-L1 cells with or without siRNA against KDM4A.
(F andG) Time-dependent recruitment of PPARg, KDM4A, andGPS2 to theRETN (F),ATGL, andHSL (G) promoters at days 0, 2, 4, and 6 of 3T3-L1 differentiation.
All graphic data are ±SD, with corresponding p values indicated as follow: *p < 0.08; **p < 0.05; ***p < 0.01.
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during adipocyte differentiation. As predicted, GPS2 and
KDM4A presence precedes PPARg recruitment on each regula-
tory region (Figures 3F and 3G), thus confirming their role in prim-
ing a specific subset of promoters for subsequent gene
activation.
GPS2 Regulates Genome-wide Localization of KDM4A
Based on the consistent results observed on the regulatory re-
gions of HSL, ATGL, and RETN, we hypothesized that the
same strategy could be employed to modulate the expression
of a larger cohort of genes. Thus, we determined KDM4A
genome-wide localization in differentiated 3T3-L1, in the pres-
ence or absence of GPS2, and overlapped it with GPS2-binding
profile. Despite the low number of binding sites detected (1,657
in cells transfected with siCTL and 1,349 in cells transfected with
siGPS2) (Figure S3A), a significant interaction was observed
between GPS2 and KDM4A, with almost 50% of KDM4A peaks
overlapping with GPS2 binding (Figure 4A). KDM4A-binding pro-
file appeared to be equally divided among intergenic regions and
promoters/intronic regions (Figure S3B). Notably, we found that
KDM4A binding to GPS2-bound promoters was stronger than
KDM4A binding to GPS2-bound enhancers or other locations,
with a very large percentage of KDM4A-regulated promoters be-
ing enriched for GPS2 binding (163 out of 203 peaks) (Figure 4A).
Most importantly, KDM4A binding to promoters, but not to other
regions, was specifically reduced upon GPS2 downregulation
by siRNA transfection, as indicated by a general reduction in
the overall number of peaks and a significant reduction in tag
density and read counts over each peak (Figures 4B, 4C, and
S3C). Thus, our findings indicate that GPS2 is required on a num-
ber of genes to promote KDM4A binding to regulated promoters.
To further confirm that this strategy is employed for regulating
PPARg transcriptional activity, we asked to which extent the
KDM4A program overlaps with PPARg-binding sites. Again,
whereas only 35% of overall KDM4A peaks were in common
with PPARg peaks (568 out of 1,657 peaks), almost 50% of
KDM4A-bound promoters were in common with PPARg peaks
(93 out of 203 peaks). On this subset, a striking overlap with
GPS2 binding was observed, with more than 80% of the com-
mon KDM4A/PPARg promoter peaks being co-occupied by
GPS2 (75 out of 93 peaks) (Figure 4E). Thus, our data together
suggest the existence of a defined set of promoters that are
coregulated by PPARg/KDM4A/GPS2 based on a dedicated
regulatory strategy, which depends on GPS2-mediated regula-
tion of KDM4A occupancy to promote histone demethylation
and allow PPARg recruitment. To validate this hypothesis on a
representative subset of the 93 candidate target genes identified
by genome-wide analyses, we picked 6 random genes and
measured the effect of downregulating either GPS2 or KDM4A
on their expression. As shown in Figure 4E, in either condition,
the expression of all but one gene was severely downregulated,
including syntaxin-16 (STX16), pantothenate kinase 1 (PANK1),
LETM1 Domain Containing 1 protein (LETMD1), insulin receptor
1 (INSR1), limb development membrane protein 1 (LMBR1), and
retinoblastoma-like 2/p130 (RBL2). Also, downregulating GPS2
by siRNA was sufficient to loose PPARg recruitment to each of
their promoters as measured by ChIP (Figure 4F), thus confirm-
ing that our genome-wide approach has identified a specifictranscriptional program regulated via the priming strategy we
have dissected on the promoters of RETN, HSL, and ATGL.
Furthermore, comparison between the promoter locations
that are marked by GPS2, KDM4A, and PPARg in differentiated
adipocytes with locations bound by NCoR and/or SMRT in pre-
adipocytes also revealed an extensive overlapping, with more
than 70% of the peaks that are coregulated by GPS2/KDM4A/
PPARg being marked by corepressors prior to differentiation
(Figure 4G). This suggests that recruitment of both KDM4A and
GPS2 to the specific target promoters that need to be primed
for PPARg binding may occur in the preadipocyte state via the
NCoR/SMRT complex. Demethylation of these regulatory re-
gions by KDM4A depends on the presence of GPS2 and is
required for later recruitment of PPARg.
GPS2 Inhibition of RNF8 Stabilizes the Histone
Demethylase KDM4A
Next, we addressed the molecular mechanism of GPS2-medi-
ated regulation of KDM4A promoter occupancy and histone
demethylation. Based on our recent findings that cytosolic
GPS2 modulates inflammatory responses via inhibition of the
ubiquitin machinery required for activation of the TNF-a pathway
(Cardamone et al., 2012), we asked whether GPS2 actions in the
nucleus could reflect a similar mechanism. Intriguingly, the E2
ubiquitin-conjugating enzyme regulated by GPS2 in the cytosol,
Ubc13, also functions as a chromatin-modifying factor for DNA
damage-induced ubiquitination of histone H2A in the nucleus,
the major difference being that in the cytoplasm, Ubc13 prefer-
entially associates with the TRAF family of E3 ligases to regulate
inflammatory responses, whereas in the nucleus, it partners
with the E3 RING ligases RNF8 and RNF168 (Huen et al., 2007;
Mailand et al., 2007; Stewart et al., 2009). Because RNF8 was
previously reported to function as a putative coactivator for the
PPARg heterodimeric partner, RXR (Takano et al., 2004), and
was shown to regulate the ubiquitin-dependent degradation of
KDM4A at DNA damage sites (Bohgaki et al., 2011), we asked
whether GPS2 could regulate chromatin remodeling and pro-
moter accessibility via inhibition of Ubc13/RNF8-dependent
ubiquitination and degradation of KDM4A.
First, we investigated whether RNF8 and Ubc13 were bound
to DNA because both enzymes would have to be recruited on
the same genomic locations regulated by GPS2 and PPARg
for GPS2 to function as a local inhibitor of the RNF8/Ubc13
ubiquitin-conjugating machinery. In agreement with this hypo-
thesis, we found that both RNF8 and Ubc13 are recruited on
the RETN, HSL, and ATGL promoters in differentiated 3T3-L1
(Figure 5A). Moreover, their binding to chromatin is not affected
by GPS2 downregulation by siRNA, as would be expected if their
enzymatic activities, rather than their recruitment to chromatin,
were regulated by GPS2. Importantly, RNF8 downregulation by
itself does not affect HSL, ATGL, and RETN gene expression;
however, it is sufficient to rescue the expression of the same
genes when impaired by siGPS2 transfection (Figure 5B). These
results confirm that GPS2 is required to prevent the expression
of these genes to be inhibited by promoter-bound RNF8.
Next, we investigated by ChIP analysis whether the re-
cruitment of KDM4A to the regulatory regions of the genes
under examination was affected by downregulating RNF8 or byCell Reports 8, 163–176, July 10, 2014 ª2014 The Authors 169
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GPS2-mediated regulation of RNF8. These experiments
confirmed that (1) KDM4A binding to the ATGL and RETN pro-
moters significantly increased upon RNF8 downregulation (Fig-
ure 5C), (2) KDM4A binding to these promoters was highly down-
regulated in the absence of GPS2 (Figure 5D), and (3) the loss of
KDM4A occupancy in absence of GPS2 was dependent on
RNF8, as indicated by the full rescue observed upon RNF8
downregulation (Figure 5D). As expected, PPARg binding was
similarly restored upon RNF8 downregulation as a consequence
of KDM4A-recovered recruitment to the selected promoters
(Figure 5C).
Finally, we tested the interaction between GPS2 and RNF8
in vivo and in vitro by coimmunoprecipitation (coIP) in 293T cells
and by glutathione S-transferase (GST) pull-down using purified
proteins. A significant interaction was observed in both experi-
mental settings (Figure S4A), with RNF8 binding specifically
to the N terminus domain of GPS2 (aa 2–99) (Figure S4B), even
in absence of Ubc13 (Figure S4C). To address the functionality
of such interaction, we performed in vitro ubiquitination in a
fully reconstituted system, which indicated that RNF8/Ubc13-
dependent ubiquitin chain synthesis was inhibited by GPS2 in
a concentration-dependent manner (Figure 5E). In addition, to
directly address whether GPS2 presence is required for protect-
ing KDM4A from Ubc13-dependent ubiquitination, we investi-
gated KDM4A protein stability and its ubiquitination in vitro.
Whereas KDM4A protein stability was only slightly decreased
in nuclear extracts from 3T3-L1 cells transfected with siRNA
against GPS2 (Figure S4D), KDM4A polyubiquitination by
Ubc13/RNF8 in vitro was strongly inhibited by recombinant
GPS2 (Figure 5F). Combined, these results show that GPS2
binds directly to RNF8, in addition to Ubc13, and by doing so,
inhibits their enzymatic activity. They also suggest that GPS2
is not responsible for regulating the global level of KDM4A in
the cell but is rather required at the chromatin level to regulate
ubiquitin-dependent dismissal of KDM4A from specific regu-
latory regions.
DISCUSSION
A critical step in the regulation of adipocyte differentiation is an
extensive reprogramming of gene expression that includes the
activation of a large cohort of adipogenic genes, which are
kept under negative regulation in undifferentiated cells. A wealth
of studies has contributed to the identification of the complex
network of transcription factors and regulatory complexes that
drive these changes (Farmer, 2006; Rosen and MacDougald,
2006). Among others, genome-wide analysis of corepressors
binding to DNA during the progression of adipogenesis hasFigure 4. Genome-wide Analysis of GPS2-Mediated Regulation of KDM
(A) Overlapping between GPS2 and KDM4A ChIP-seq data sets in differentiated
(B) KDM4A binding is specifically reduced on promoters co-occupied by GPS2
statistically significant: p = 1.73 3 105, Welch two-sample t test.
(C) No statistically significant difference is observed on nonpromoter regions.
(D) Heatmaps showing the overlapping of KDM4A peaks with GPS2 and PPARg
(E) qPCR analysis showing decreased expression of six representative genes up
(F) ChIP analysis showing dismissal of PPARg from their promoters upon GPS2
(G) Heatmaps showing overlapping of GPS2, NCoR, and SMRT peaks around threvealed a model in which the corepressors SMRT and, to a
lesser extent, NCoR function in concert with two DNA-binding
partners, namely C/EBPb on distal sites and Kaiso on proximal
sites, to block adipogenic gene expression in undifferentiated
cells (Raghav et al., 2012). Here, genome-wide localization anal-
ysis in murine adipocytes of GPS2, a component of the NCoR
and SMRT corepressor complexes, reveals that GPS2 plays
complementary roles in gene repression and gene activation
during adipogenesis. In particular, our findings define a specific
transcriptional program coregulated by GPS2 and PPARg that is
characterized by recruitment of PPARg to promoter-specific
binding sites rather than distal sites, as observed for the large
majority of PPARg-regulated genes (Everett and Lazar, 2013).
On these target promoters, GPS2 acts as a pioneering factor
for PPARg recruitment based on its ability to inhibit the E3
ubiquitin ligase RNF8, protect KDM4A from degradation and,
therefore, promote histone H3K9 demethylation.
Intriguingly, mammalian KDM4A has been linked to both tran-
scriptional repression, in association with the NCoR complex,
and activation functions, mediated by nuclear receptors, in a
fashion very similar to GPS2 itself (Zhang et al., 2005; Shin and
Janknecht, 2007). Because Drosophila KDM4A plays an essen-
tial function in mediating ecdysteroid hormone signaling during
larva development (Tsurumi et al., 2013), epigenetic regulation
by KDM4 demethylases may be a conserved strategy to modu-
late changes in chromatin structure at promoters regulated
by nuclear receptors. Future studies will indicate whether the
regulatory component mediated by GPS2 also represents a
conserved mechanism contributing to the regulation of other
nuclear receptors’ activity, including LXR, ER, and AR. Impor-
tantly, regulatory mechanisms based on stabilization of histone
demethylases may represent unexplored druggable targets in
the treatment of human diseases as indicated by the recent
finding of KDM4B stabilization by Hsp90 in tumors (Ipenberg
et al., 2013).
One important difference compared to previously reported
models of KDM-mediated regulation of gene expression is that
the regulatory strategy that emerges from our results is based
on H3K9 demethylase activity being required to prime chromatin
for nuclear receptor binding rather than being brought in by the
liganded nuclear receptor as a chromatin-remodeling cofactor
(Garcia-Bassets et al., 2007; Wang et al., 2007; Guo et al.,
2012; Tsurumi et al., 2013). Although together these results
confirm the importance of H3K9me as a mechanism for defining
groups of commonly coordinated genes, it is possible that the
different nature of regulation achieved via demethylation reflects
the fact that we have analyzed PPARg-mediated events in a
developmental program, rather than in response to hormonal4A Binding to Chromatin
3T3-L1 cells.
and KDM4A as shown by box plot and tag density profile. The reduction is
peaks on promoters.
on KDM4A or GPS2 transient downregulation in differentiated 3T3-L1 cells.
downregulation.
e KDM4A peaks located on promoter regions.
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Figure 5. Inhibition of RNF8 Enzymatic Activity Is Required for KDM4A Stabilization and Lipolytic Gene Expression
(A) ChIP for RNF8 and Ubc13 on the ATGL, HSL, and RETN promoters.
(B) Transient transfection of siRNA for RNF8 rescues siGPS2-dependent downregulation of ATGL, HSL, and RETN gene expression (left panel). No significant
change is observed upon siRNF8 transfection (right panel).
(C) Increased recruitment of KDM4A on ATGL and RETN promoters is observed after RNF8 downregulation via specific siRNA.
(legend continued on next page)
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signaling cues. Indeed, during the early phases of adipogenesis,
when PPARg is not yet expressed, other transcription factors,
such as C/EBPb, RXR, and GR, are required to promote gene
expression changes that will determine cell fate. As a result,
PPARg recruitment to the regulatory regions governing adipo-
genic gene expression is likely influenced by changes in chro-
matin status determined prior to its expression (Steger et al.,
2010; Siersbæk et al., 2012; Everett and Lazar, 2013). Thus, in
the context of adipogenesis, our results support the idea of
an ‘‘assisted loading’’ model in which priming of a ‘‘de novo’’
regulatory unit is achieved by remodeling events that are
required to promote a chromatin open state permissive for
PPARg binding (Voss et al., 2011; Madsen et al., 2014).
Intriguingly, a different member of the KDM/JMJD2 family,
KDM4B, is recruited by C/EBPb during the early mitotic clonal
expansion phase of adipocyte differentiation to demethylate its
own target genes (Guo et al., 2012). Because C/EBPb and
PPARg often work in tandem in the regulation of proadipogenic
gene expression, it is tempting to speculate that similar epige-
netic strategies, with different demethylases, might be employed
to regulate priming of different subsets of PPARg target genes.
Accordingly, our findings indicate that GPS2/KDM4A coregu-
latory activity is targeted toward a specific subset of PPARg
target genes, including the two master regulators of lipolysis:
ATGL and HSL. Increased expression of these genes in adipo-
cytes from aP2-GPS2 mice is associated with increased HSL
phosphorylation, thus suggesting that both basal lipolysis and
induced lipolysis are hyperactivated in the adipose tissue of
GPS2 transgenic mice. Additional studies will be required to
confirm whether the increase in ATGL and HSL expression
described here translates into an effective increase in the rate
of lipolysis in vivo, and to address how the increase in lipolysis
contributes to the general metabolic profiling of aP2-GPS2
transgenic mice. Nonetheless, we speculate that increased
mobilization of lipids from the adipose tissue due to upregulated
lipolysis might be contributing to the observed excessive fat
deposition in peripheral organs (Cardamone et al., 2012). Intrigu-
ingly, genetic inactivation of another component of the NCoR
complex, TBLR1, blunts the lipolytic response of white adipo-
cytes through the impairment of cyclic AMP-dependent signal
transduction (Rohm et al., 2013), thus suggesting that GPS2
and associated cofactors play a critical role in the regulation of
lipid mobilization.
Finally, the identification of a regulatory strategy for PPARg-
mediated transcription based on the control of the local chro-
matin architecture via stabilization of a histone demethylase,
together with our recent report of GPS2-mediated inhibition of
JNK activation in adipose tissue and macrophages, indicates
that the ability of GPS2 to regulate Ubc13-dependent ubiquitin
signaling, both inside and outside the nucleus, plays a central
role in key metabolic organs. Because a recent study in human(D) ChIP analysis in differentiated 3T3-L1 showing that dismissal of PPARg and
RNF8 via specific siRNA.
(E) In vitro ubiquitination assay with recombinant E1 and E2 (Ubc13/Uev1a) and b
RNF8 enzymatic activity in a dose-dependent manner.
(F) In vitro ubiquitination assay showing that polyubiquitination of KDM4A by RN
All graphic data are ±SD, with corresponding p values indicated as follow: *p < 0adipose tissue indicates that GPS2-mediated transcriptional
repression is also critical for the regulation of inflammatory genes
(Toubal et al., 2013), together, these observations suggest that
GPS2 may become an interesting target for novel therapeutic
approaches toward metabolic diseases.
EXPERIMENTAL PROCEDURES
Mice
The aP2-GPS2 transgenic mice were previously described (Cardamone et al.,
2012). All animal experiments were performed in accordance with the NIH
guide for the care and use of laboratory animals and with the approval of the
Institutional Animal Care and Use Committee of Boston University.
Reagents and Antibodies
Anti-GPS2 rabbit antibody was generated against a C-terminal peptide
(Cardamone et al., 2012). Other antibodies were purchased from Santa Cruz
Biotechnology (anti-PPARg [H-100], anti-Ubc13 [YD-16], anti-Ub [P4D1],
and anti-HDAC2 [H54]) or from Sigma-Aldrich (anti-RNF8 [AV40071], and
anti-Ubc13 [AV43437]). Also, anti-Flag M2 and mouse anti-HA (Upstate
Biotechnology), rat anti-HA (Roche), and anti-KMD4A (Abcam; ab47984)
were used. siRNAs specific for GPS2, RNF8, and KDM4A were purchased
from Invitrogen (Silencer Select siRNAs).
Lipolysis Assay
Lipolysis assays were performed in mouse primary adipocytes, isolated as
described by Carswell et al. (2012), or in mature 3T3-L1 cells after 6–8 days
of induced differentiation. 3T3-L1 cells were grown, transfected, and induced
to differentiate as previously described (Cardamone et al., 2012). To measure
induced lipolysis, cells were preincubated in Dulbecco’s modified Eagle’s me-
dium without phenol red and supplemented with 4% BSA fatty acid-free for
5 hr prior to 1 hr stimulation with 10 mM of isoproterenol (Calbiochem, Merck).
Protein-Interaction Studies and In Vitro Ubiquitination
Nuclear and whole-cell protein extraction was performed as previously
described (Cardamone et al., 2012). For coIP experiments, extracts were incu-
bated with the specific antibody overnight at 4C and isolated on protein A/G
agarose beads (Invitrogen). GST-fusion proteins containing different regions
of GPS2 (GPS2 A, aa 2–99; GPS2 B, aa 2–137; GPS2-C, aa 2–155; GPS2-D,
aa 2–187; GPS2-E, aa 155–327; and GPS2-F, aa 212–327) or GPS2 full-length
were expressed in BL21 bacteria and purified as described (Perissi et al.,
2004). For GST pull-down studies, the immobilized GST-fusion proteins
were incubated with TnT RNF8 (Promega). Ubiquitination assays were carried
out as previously described using 50 nM E1, 5 mg ubiquitin, and 200 nM
Ubc13-Uev1a (Cardamone et al., 2012). RNF8 and GPS2 were produced as
GST or His fusion proteins and purified from bacterial lysates. Full-length
KDM4A was produced using the Promega TnT kit and purified by anti-Flag
immunoprecipitation.
ChIP Assay, RNA Isolation, and RT-PCR Analysis
ChIP was performed as described (Perissi et al., 2004). For ChIP-seq sample
preparation, 3T3-L1 cells were subjected to standard ChIP prior to library
preparation. For expression experiments, RNA was isolated using the RNeasy
Kit (QIAGEN). First-strand cDNA synthesis from total RNA template was
performed with the IScript cDNA Synthesis System (Bio-Rad), followed by
SYBR Green quantitative PCR (qPCR) amplification. Normalization was per-
formed using specific amplification of Cyclophilin A, and qPCRs were per-
formed in triplicate for each biological duplicate experiment. All ChIP andKMD4A from ATGL, HSL, and RETN regulatory units is rescued by ablation of
acterially expressed and purified E3 ligase (RNF8) showing that GPS2 inhibits
F8/Ubc13 is inhibited by GPS2.
.08; **p < 0.05; ***p < 0.01.
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qPCRs were repeated at least three times, and representative results were
shown. Primers used are specific for the regions indicated, and their se-
quences are available upon request. Data are shown as averages between
the triplicates plus SD. Significance is calculated by paired Student’s t test.
ChIP-Seq and Bioinformatic Analysis of ChIP-Seq Data Sets
ChIP-seq samples were subjected to standard ChIP; libraries were prepared
and sequenced on a GAII sequencing machine according to Illumina’s stan-
dard protocol. PPARg, RXR, and Pol2 ChIP-seq data sets were downloaded
from NCBI Gene Expression Omnibus (GEO) series GSE13511 (Lim et al.,
2013); NCoR and SMRT ChIP-seq data were downloaded from ArrayExpress
E-MTAB-103 (Raghav et al., 2012). H3K36me3, H3K4me1, H3K4me2, and
H3K27ac ChIP-seq data sets were downloaded from NCBI GEO series
GSE20752 (Mikkelsen et al., 2010). Sequence alignment of ChIP-seq sam-
ples was performed by using Bowtie or BFAST to mm8 or mm9 assembly
of the mouse genome. The HOMER software suite was used to call the
peaks for GPS2, NCoR, SMRT, RXR, and PPARg ChIP-seq data sets. GPS2
peaks are considered on promoters if the peak summit is within 1 kb
and +400 bp around the transcription start site (TSS). To define GPS2 peaks
on enhancers, we extended the H3K4me1 and GPS2 peaks ±1 kb around
the peak summit, and the intersections were computed by using BedTools.
The heatmaps of ChIP-seq data sets were displayed in TM4/MeV. GO/
pathway analysis was computed by DAVID/EASE, ToppGENE, HOMER,
and GREATs. The enrichment analysis of GPS2 binding near adipogenesis-
regulated genes was based on hypergeometric distribution and was com-
puted in R. To compute the differentially expressed genes based on Pol2
and H3K36me3 ChIP-seq data sets, we used mm9 RefSeq gene annotations
and BedTools to count the sequencing reads on each gene. Statistically
significant differentially expressed genes were defined using edgeR (false
discovery rate <0.01) and a supplementary read density criterion of at least
two reads per kilobase gene length.ACCESSION NUMBERS
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